Evidence map›Paper›PMID 34927340›Full record

ArticleHemodialysis international. International Symposium on Home Hemodialysis2022

Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patients.

Bruce Spinowitz, Kieran McCafferty, Steven Fishbane, Masafumi Fukagawa, Nicolas Guzman, Martin Ford, Anjay Rastogi, Sunil Bhandari

Open access · hybridAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Hemodialysis international. International Symposium on Home Hemodialysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Management of hyperkalemia: Expert consensus from Kuwait - a Modified Delphi Approach.International journal of nephrology and renovascular disease · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 4 countries.

Bruce SpinowitzDepartment of Medicine, NewYork-Presbyterian Queens, Queens, NY, USA.
Kieran McCaffertyDepartment of Nephrology, Barts Health NHS Trust, London, UK.ORCID 0000-0002-0762-2270
Steven FishbaneDepartment of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA.
Masafumi FukagawaDivision of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Nicolas GuzmanGlobal Medicines Development, AstraZeneca BioPharmaceuticals Research and Development, Gaithersburg, MD, USA.
Martin FordDepartment of Renal Medicine, King's College Hospital NHS Trust, London, UK.
Anjay RastogiUCLA CORE Kidney Program, University of California Los Angeles, Los Angeles, CA, USA.
Sunil BhandariDepartment of Renal and Transplant Medicine, Hull University Teaching Hospitals NHS Trust, Hull, UK.
AstraZeneca (Poland) · PLBarts Health NHS Trust · GBDonald & Barbara Zucker School of Medicine at Hofstra/Northwell · USKing's College - North Carolina · USNew York Hospital Queens · USTokai University · JPUniversity of California, Los Angeles · USUniversity of Hull · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HyperkalemiaRenal DialysisHumansPotassiumSilicatesPotassiumSilicatessodium zirconium cyclosilicatedosefluid balancehemodialysishyperkalemiapotassiumsodium zirconium cyclosilicate

Identifiers

PMID34927340
PMCPMC9299877
OpenAlexW4200371886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.